USP’s Medicine Supply Map - the first of its kind in the world - enhances visibility into the upstream medicines supply chain to help governments, manufacturers, distributors, and providers identify and address vulnerabilities, lessen quality risks, reduce the frequency and duration of potential drug shortages, and protect patients.
“USP’s Medicine Supply Map is an early-warning system for possible drug shortages, whether due to global health crises, natural disasters, geopolitical events, or quality-related issues in manufacturing.”
- Vimala Raghavendran, Senior Director, USP Pharmaceutical Supply Chain Center
Policymakers are increasingly focused on addressing risks and vulnerabilities in pandemic preparedness infrastructure. The Medicine Supply Map leverages insights derived from the use of USP quality standards in more than 22 thousand locations around the world, spanning 92 percent of generic medicines approved in the U.S. It aggregates more than 40 external datasets and 250 million data points to quantify risk and resilience in the upstream pharmaceutical supply chain.
The Medicine Supply Map provides insights on supply chain vulnerabilities to drive decision-making.
Pinpoint supply chain risks
Leveraging multiple data sources, the Medicine Supply Map helps identify, characterize, and quantify risk factors to help guard against over-reliance on over-concentrated sources, reduce disruptions, and build resilience.
Sign up to receive resources and updates related to USP’s work to strengthen the global supply of medicines
Supply resilience scores to address risks
Data analytics shed light on factors that help drive resilience in the pharmaceutical supply chain. Vulnerable populations can be particularly at risk when shortages occur, as with pediatric oncology medicines.
Drug supply chains: challenges, risks, and opportunities
The global medicine supply chain is complex, fragmented, and opaque. What are some of the challenges and how can the medicine supply chain become more resilient?
Building adequate supplies of critical medicines
“Ensuring a resilient US prescription drug supply” pinpoints key supply chain issues and offers practical recommendations.